Experience

Davis Polk is advising Novo Nordisk on its $145 million acquisition of the U.S. and Canadian rights to Macrilen from Strongbridge Biopharma Plc. Novo Nordisk will also acquire newly issued…

Davis Polk advised the underwriters and joint global coordinators in the initial public offering and listing on the Hong Kong Stock Exchange and the international offering in reliance on…

Davis Polk advised the initial purchasers in connection with a $215 million Regulation S only offering by Oceanwide Holdings International Development III Co., Ltd of its 12.00%…

Davis Polk is advising an ad hoc group of secured lenders in connection with the proposed prepackaged chapter 11 reorganization of Dixie Electric, LLC and certain of its affiliates. On…

Davis Polk advised the representatives of the underwriters in connection with the $50 million initial public offering of 6,250,000 ordinary shares of Gamida Cell Ltd. The ordinary…

Davis Polk advised the initial purchasers in connection with a $500 million offering of 7.000% senior notes due 2026 by JBS Investments II GmbH and guaranteed by JBS S.A., which were…

Davis Polk is advising Mitsubishi UFJ Lease & Finance Co., Ltd. (“MUL”) on its acquisition of ENGS Holdings Inc. from a group of shareholders represented by Aquiline Capital Partners…

Davis Polk advised Tokyu Fudosan Holdings Corporation in connection with a follow-on offering of 80,436,000 shares of common stock. In addition, the underwriters have over-allotment options…

Davis Polk advised StoneCo Ltd. on its $1.4 billion initial public offering of 58,333,333 shares of Class A common stock, which includes the full exercise of the underwriters’ option to…

Davis Polk advised the sole dealer manager in connection with a cash tender offer by Riviera Resources, Inc. for 6,062,179 shares of its common stock at a purchase price of $22.00 per…